Elixir Pharmaceuticals, Inc. announced that its partner, Siena Biotech S.p.A., has commenced Phase 1 clinical testing of Elixir’s potent, first-in-class SIRT1 (sirtuin-1) inhibitor for the treatment of Huntington’s Disease…
Filed under: Huntingtons Disease - Trackback Uri